Global Cardiovascular Risk Consortium

Status Completed

Clinical Trial Summary

The Global Cardiovascular Risk Consortium (GCVRC) comprises harmonized data from nearly 1.7 Mio individuals of 126 cohorts across 43 countries and aims to elucidate the distribution of five major cardiovascular risk factors (body mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes) and their impact on cardiovascular disease (CVD) by geographical region and sex.

Clinical Trial Description

Previous literature reported a small number of modifiable risk factors that might explain up to 90% of certain CVD subtypes. If and to what extent regional differences in risk factor levels contribute to new-onset CVD remains to be elucidated. In the Global Cardiovascular Risk Consortium (GCVRC) we focus on five major cardiovascular risk factors: Body mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes. We aim to show the extent to which the distribution, population attributable risk, and predictive value of these factors differ geographically and by sex. Understanding of these issues is essential to guide regionally effective CVD prevention and therapy strategies, to determine residual risk, and to improve global cardiovascular health. The GCVRC uses individual-level harmonized data from nearly 1.7 million individuals in 126 cohorts across 43 countries, categorized in 8 geographical regions (based on amodification of WHO regions) - North America, Latin America, Sub-Saharan Africa, North Africa and Middle East, Western Europe, Eastern Europe and Russia, Asia, Oceania. Cox regression analyses and population attributable fractions (PAFs) for 10-year incident CVD are calculated for the five risk factors by geographical region and sex to determine the percentage of CVD burden that may be preventable by control of these risk factors. The results will influence regionally adapted prevention strategies to reduce the global CVD burden. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05466825
Study type	Observational
Source	Universitätsklinikum Hamburg-Eppendorf
Contact
Status	Completed
Phase
Start date	September 20, 2019
Completion date	February 23, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04043052` - Mobile Technologies and Post-stroke Depression	N/A
Completed	`NCT04034069` - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial	N/A
Suspended	`NCT03869138` - Alternative Therapies for Improving Physical Function in Individuals With Stroke	N/A
Completed	`NCT04101695` - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects	N/A
Terminated	`NCT03052712` - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies	N/A
Completed	`NCT00391378` - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)	N/A
Recruiting	`NCT06204744` - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial	N/A
Active, not recruiting	`NCT06043167` - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Enrolling by invitation	`NCT04535479` - Dry Needling for Spasticity in Stroke	N/A
Completed	`NCT03985761` - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke	N/A
Recruiting	`NCT00859885` - International PFO Consortium	N/A
Recruiting	`NCT06034119` - Effects of Voluntary Adjustments During Walking in Participants Post-stroke	N/A
Completed	`NCT03622411` - Tablet-based Aphasia Therapy in the Chronic Phase	N/A
Completed	`NCT01662960` - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke	N/A
Recruiting	`NCT05854485` - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke	N/A
Active, not recruiting	`NCT05520528` - Impact of Group Participation on Adults With Aphasia	N/A
Active, not recruiting	`NCT03366129` - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed	`NCT05805748` - Serious Game Therapy in Neglect Patients	N/A
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Recruiting	`NCT05993221` - Deconstructing Post Stroke Hemiparesis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.